1
Mcswiggen James, Haeberli Peter, Beigelman Leonid: Rna interference mediated treatment of parkinson disease using short interering nucleic acid (sina). Sirna Therapeutics, Mcswiggen James, Haeberli Peter, Beigelman Leonid, TERPSTRA Anita J, May 19, 2005: WO/2005/045034 (83 worldwide citation)

The present invention concerns methods and reagents useful in modulating Parkinson genes, for example, PARK1 (SNCA), PARK2, PARK7, and/or PARK5 gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, ...


2
Blatt Lawrence M, Seiwert Scott, Beigelman Leonid, Kercher Timothy, Kennedy April L, Andrews Steven W: Novel inhibitors of hepatitis c virus replication. Intermune, Array Biopharma, Blatt Lawrence M, Seiwert Scott, Beigelman Leonid, Kercher Timothy, Kennedy April L, Andrews Steven W, MALLON Joseph J, January 10, 2008: WO/2008/005511 (58 worldwide citation)

The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a, subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a su ...


3
Beigelman Leonid, Seiwert Scott D, Blatt Lawrence M, Andrews Steven, Haas Julia: Compounds and methods for inhibiting hepatitis c viral replication. Intermune, Array Biopharma, Beigelman Leonid, Seiwert Scott D, Blatt Lawrence M, Andrews Steven, Haas Julia, MALLON Joseph J, April 19, 2007: WO/2007/044893 (56 worldwide citation)

Macrocyclic compounds having the structures described herein arc useful for inhibiting replication of the hepatitis C virus (HCV). In preferred embodiments, the compounds are active against both the NS3 protease and the NS3 helicase of HCV. Formulae (I), (II), (III), (IV) and (V).


4
Blatt Lawrence M, Pan Lin, Seiwert Scott, Andrews Steven W, Martin Pierre, Schumacher Andreas, Beigelman Leonid, Liu Jyanwei, Condroski Kevin, Jiang Yutong, Kaus Robert, Kennedy April, Kercher Timothy, Lyon Michael, Wang bin: Novel macrocyclic inhibitors of hepatitis c virus replication. Intermune, Array Biopharma, Blatt Lawrence M, Pan Lin, Seiwert Scott, Andrews Steven W, Martin Pierre, Schumacher Andreas, Beigelman Leonid, Liu Jyanwei, Condroski Kevin, Jiang Yutong, Kaus Robert, Kennedy April, Kercher Timothy, Lyon Michael, Wang bin, MALLON Joseph J, November 13, 2008: WO/2008/137779 (56 worldwide citation)

The embodiments provide macrocyclic compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treatin ...


5
Andrews Steven W, Seiwert Scott, Beigelman Leonid, Blatt Lawrence, Buckman Brad: Novel peptide inhibitors of hepatitis c virus replication. Intermune, Array Biopharma, Andrews Steven W, Seiwert Scott, Beigelman Leonid, Blatt Lawrence, Buckman Brad, HART Daniel, November 20, 2008: WO/2008/141227 (54 worldwide citation)

The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a sub ...


6

7
Feinstein Elena, Aygun Huseyin, Skaliter Rami, Kalinski Hagar, Mett Igor, Mcswiggen James, Beigelman Leonid: Novel sirna structures. Quark Pharmaceuticals, Feinstein Elena, Aygun Huseyin, Skaliter Rami, Kalinski Hagar, Mett Igor, Mcswiggen James, Beigelman Leonid, QUARK PHARMACEUTICALS, April 9, 2009: WO/2009/044392 (31 worldwide citation)

The invention relates to siRNA compounds possessing novel sequences and structural motifs which down-regulate the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention a ...


8
Seiwert Scott, Beigelman Leonid, Buckman Brad, Stoycheva Antitsa Dimitrova, Porter Steven B, Bradford Williamson Ziegler, Serebryany Vladimir: Novel macrocyclic inhibitors of hepatitis c virus replication. Intermune, Seiwert Scott, Beigelman Leonid, Buckman Brad, Stoycheva Antitsa Dimitrova, Porter Steven B, Bradford Williamson Ziegler, Serebryany Vladimir, Mallon Joseph J, November 26, 2009: WO/2009/142842 (25 worldwide citation)

The embodiments provide compounds of the general Formulae I, II, EI, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection an ...


9
SMITH David Bernard, DEVAL Jerome, DYATKINA Natalia, BEIGELMAN Leonid, WANG Guangyi: ANALOGUES NUCLÉOTIDIQUES SUBSTITUÉS, SUBSTITUTED NUCLEOTIDE ANALOGS. ALIOS BIOPHARMA, SMITH David Bernard, DEVAL Jerome, DYATKINA Natalia, BEIGELMAN Leonid, WANG Guangyi, MILLER Kimberly J, March 29, 2012: WO/2012/040127 (14 worldwide citation)

Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.


10
Blatt Lawrence M, Seiwert Scott D, Beigelman Leonid, Radhakrishnan Ramachandran: Pyridone derivatives for modulating stress-activated protein kinase system. Intermune, Blatt Lawrence M, Seiwert Scott D, Beigelman Leonid, Radhakrishnan Ramachandran, RIN LAURES Lily, November 16, 2006: WO/2006/122154 (12 worldwide citation)

Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentag ...